Abstract
Salivary gland tumors (SGTs) present a diagnostic challenge due to their diverse histological subtypes and variable clinical behavior. This research conducted a retrospective analysis of SGT cases diagnosed and managed at a tertiary care center between 2017 and 2022. Clinical and pathological data were retrieved from medical records and histopathology reports. Statistical analysis was performed to identify factors associated with recurrence and survival outcomes. A total of 150 SGT cases were included, comprising 70% benign and 30% malignant tumors. Pleomorphic adenoma and adenoid cystic carcinoma were the most prevalent benign and malignant subtypes, respectively. Surgical resection was the primary treatment modality, with varying recurrence rates observed among different treatment groups. The current study provides insights into the histological variations and clinical outcomes of SGTs. Surgical resection remains the mainstay of treatment, with adjuvant therapy reserved for cases with adverse prognostic factors. Further research is needed to optimize therapeutic strategies and improve patient outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
